🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Rüdiger Hehlmann

University of Mannheim

ORCID: 0000-0002-3107-485X

Also affiliated with Heidelberg University, Medizinische Fakultät Mannheim, Heidelberg University

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States”.

Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States

UNC Libraries(2020)10.17615/h6kv-p452
N/A
0DataRank · unranked
0 citations

François Guilhot, Martin Müller, Jiřı́ Mayer, Richard A. Larson, Susanne Saußele +14 more

Management of chronic myeloid leukemia in 2025

Cancer(2025)10.1002/cncr.35953
N/A
0DataRank · unranked
37 citations

Massimo Breccia, Fadi Haddad, Rüdiger Hehlmann, Ghayas C. Issa, Hemant Malhotra +5 more

SOHO State of the Art Updates and Next Questions | Choosing the Best Frontline BCR::ABL1 Tyrosine Kinase Inhibitor in Chronic Myeloid Leukemia—How to Define the Treatment Value?

Clinical Lymphoma Myeloma & Leukemia(2025)10.1016/j.clml.2025.10.001
N/A
0DataRank · unranked
0 citations

Elias Jabbour, Massimo Breccia, Rüdiger Hehlmann, Hemant Malhotra, Franck E. Nicolini +3 more